HP INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HP INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $55.30B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $53.56B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $53.72B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $62.91B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $63.46B | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $56.64B | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $58.76B | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $58.47B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $52.06B | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | $48.24B | Dec 13, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $11.39B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $11.82B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $11.51B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $12.26B | Dec 13, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.53B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $2.78B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $3.26B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $3.13B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $6.54B | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $2.82B | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $3.15B | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $5.33B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $2.53B | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | $2.50B | Dec 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $3.17B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $3.82B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $3.46B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $4.56B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $5.36B | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $3.44B | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $3.88B | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $3.83B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $3.37B | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | $3.55B | Dec 13, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.60B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $1.64B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $1.58B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $1.65B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $1.85B | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $1.48B | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $1.50B | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $1.40B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $1.19B | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | $1.21B | Dec 13, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.82B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $5.66B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $5.36B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $5.26B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $5.73B | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $4.90B | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $5.37B | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $5.10B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $4.53B | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | $3.83B | Dec 13, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $3.70B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $3.75B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $3.57B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $4.46B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $6.41B | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $4.32B | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $4.65B | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $4.53B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $3.68B | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | $3.25B | Dec 13, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $41.77B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $39.91B | Dec 10, 2025 |
| FY2024 | Oct 31, 2023 | $37.00B | Dec 13, 2024 |
| FY2023 | Oct 31, 2022 | $38.49B | Dec 18, 2023 |
| FY2022 | Oct 31, 2021 | $38.61B | Sep 11, 2023 |
| FY2021 | Oct 31, 2020 | $34.68B | Dec 9, 2021 |
| FY2020 | Oct 31, 2019 | $33.47B | Dec 10, 2020 |
| FY2019 | Oct 31, 2018 | $34.62B | Dec 12, 2019 |
| FY2018 | Oct 31, 2017 | $32.91B | Dec 13, 2018 |
| FY2017 | Oct 31, 2016 | $28.99B | Dec 15, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($346.00M) | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | ($1.32B) | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | ($1.07B) | Dec 10, 2025 |
| FY2025 | Oct 31, 2022 | ($3.03B) | Dec 10, 2025 |
| FY2024 | Oct 31, 2021 | ($1.64B) | Dec 13, 2024 |
| FY2023 | Oct 31, 2020 | ($2.28B) | Dec 18, 2023 |
| FY2022 | Oct 31, 2019 | ($1.21B) | Sep 11, 2023 |
| FY2021 | Oct 31, 2018 | ($639.00M) | Dec 9, 2021 |
| FY2020 | Oct 31, 2017 | ($3.41B) | Dec 10, 2020 |
| FY2016 | Oct 31, 2016 | ($3.89B) | Dec 15, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $8.71B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $8.63B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $8.59B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $8.54B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $6.80B | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $6.38B | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $6.37B | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $5.97B | Dec 10, 2020 |
| FY2018 | Nov 1, 2017 | $339.00M | Dec 13, 2018 |
| FY2019 | Oct 31, 2017 | $5.62B | Dec 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($2.03B) | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | ($2.68B) | Dec 10, 2025 |
| FY2024 | Oct 31, 2023 | ($2.36B) | Dec 13, 2024 |
| FY2023 | Oct 31, 2022 | ($4.49B) | Dec 18, 2023 |
| FY2022 | Oct 31, 2021 | ($2.47B) | Sep 11, 2023 |
| FY2021 | Oct 31, 2020 | ($1.96B) | Dec 9, 2021 |
| FY2020 | Oct 31, 2019 | ($818.00M) | Dec 10, 2020 |
| FY2019 | Nov 1, 2018 | ($730.00M) | Dec 12, 2019 |
| FY2019 | Oct 31, 2018 | ($473.00M) | Dec 12, 2019 |
| FY2018 | Oct 31, 2017 | ($2.39B) | Dec 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $3.69B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $3.24B | Dec 10, 2025 |
| FY2024 | Oct 31, 2023 | $3.11B | Dec 13, 2024 |
| FY2023 | Oct 31, 2022 | $3.15B | Dec 18, 2023 |
| FY2022 | Oct 31, 2021 | $4.30B | Sep 11, 2023 |
| FY2021 | Oct 31, 2020 | $4.86B | Dec 9, 2021 |
| FY2020 | Oct 31, 2019 | $4.54B | Dec 10, 2020 |
| FY2019 | Oct 31, 2018 | $5.17B | Dec 12, 2019 |
| FY2019 | Oct 31, 2017 | $7.00B | Dec 12, 2019 |
| FY2019 | Oct 31, 2016 | $6.29B | Dec 12, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $9.72B | Dec 10, 2025 |
| FY2024 | Oct 31, 2024 | $9.75B | Dec 13, 2024 |
| FY2023 | Oct 31, 2023 | $9.61B | Dec 18, 2023 |
| FY2022 | Oct 31, 2022 | $11.19B | Sep 11, 2023 |
| FY2021 | Oct 31, 2021 | $7.57B | Dec 9, 2021 |
| FY2020 | Oct 31, 2020 | $6.26B | Dec 10, 2020 |
| FY2012 | Oct 31, 2012 | $27.13B | Dec 27, 2012 |
| FY2011 | Oct 31, 2011 | $26.34B | Dec 14, 2011 |
| FY2010 | Oct 31, 2010 | $16.78B | Dec 15, 2010 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 2 | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | 2 | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | 3 | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | 3 | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | 5 | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | 1 | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | 2 | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | 3 | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | 1 | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | 1 | Dec 13, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 2 | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | 2 | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | 3 | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | 2 | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | 5 | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | 1 | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | 2 | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | 3 | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | 1 | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | 1 | Dec 13, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 921.00M | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | 939.00M | Dec 10, 2025 |
| FY2024 | Oct 31, 2023 | 989.00M | Dec 13, 2024 |
| FY2023 | Oct 31, 2022 | 980.00M | Dec 18, 2023 |
| FY2022 | Oct 31, 2021 | 1.09B | Sep 11, 2023 |
| FY2021 | Oct 31, 2020 | 1.30B | Dec 9, 2021 |
| FY2020 | Oct 31, 2019 | 1.46B | Dec 10, 2020 |
| FY2019 | Oct 31, 2018 | 1.56B | Dec 12, 2019 |
| FY2018 | Oct 31, 2017 | 1.65B | Dec 13, 2018 |
| FY2017 | Oct 31, 2016 | 1.71B | Dec 15, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.09B | Dec 10, 2025 |
| FY2025 | Oct 31, 2024 | $1.08B | Dec 10, 2025 |
| FY2025 | Oct 31, 2023 | $1.04B | Dec 10, 2025 |
| FY2024 | Oct 31, 2022 | $1.04B | Dec 13, 2024 |
| FY2023 | Oct 31, 2021 | $938.00M | Dec 18, 2023 |
| FY2022 | Oct 31, 2020 | $997.00M | Sep 11, 2023 |
| FY2021 | Oct 31, 2019 | $970.00M | Dec 9, 2021 |
| FY2020 | Oct 31, 2018 | $899.00M | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $894.00M | Dec 12, 2019 |
| FY2018 | Oct 31, 2016 | $858.00M | Dec 13, 2018 |